Silverback Therapeutics

Silverback Therapeutics is a biopharmaceutical company dedicated to developing ImmunoTAC therapies targeting previously inaccessible disease pathways. They have developed a new generation of systemic, locally active treatments that can effectively modulate fundamental disease pathways once considered untreatable. Silverback Therapeutics is building a platform technology that utilizes established antibody-guided approaches to target disease sites, unlocking potent immunomodulatory pathways. The company's proprietary ImmunoTAC technology and integrated R&D approach enable the design of product candidates that are systemically administrable but only act at the site of disease.